FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2924783581> ?p ?o ?g. }

• W2924783581 endingPage "62" @default.
• W2924783581 startingPage "56" @default.
• W2924783581 abstract "BLU-5937 is a small molecule that was shown to be a potent, selective and non-competitive P2X3 homotrimeric receptor antagonist. P2X3 receptors are ATP ion-gated channels located on primary afferent neurons. ATP released from damaged or inflamed tissues in the airways acts on P2X3 receptors of primary afferent neurons, triggering depolarization and action potentials that are transmitted centrally and interpreted as urge to cough. There are strong preclinical and clinical evidence supporting the role of P2X3 receptors in hypersensitization of the cough reflex, leading to chronic cough. By inhibiting P2X3 receptors on the primary sensory neurons, BLU-5937 would inhibit the hypersensitization of the cough reflex and, hence, the exaggerated cough experienced in chronic cough patients. BLU-5937 is being developed for the treatment of unexplained, refractory chronic cough. The high potency and selectivity of BLU-5937 for P2X3 homotrimeric receptors was demonstrated in vitro by inhibiting αβ-meATP-evoked P2X3 or P2X2/3 receptor activity in cloned human hP2X3 and hP2X2/3 channels expressed in mammalian cells. The IC50 of BLU-5937 for hP2X3 homotrimeric and hP2X2/3 heterotrimeric receptors was established at 25 nM and >24 μM, respectively. Furthermore, BLU-5937 (500 nM) was able to block αβ-meATP-induced sensitization and firing activity of isolated primary nociceptors in rat dorsal root ganglions (DRGs), through P2X3 homotrimeric receptor antagonism. In a guinea pig cough model, BLU-5937 (0.3, 3 and 30 mg/kg, oral) significantly reduced, in a dose-dependent fashion, the histamine-induced enhancement in the number of citric acid-induced coughs. BLU-5937 (3 and 30 mg/kg, oral) was also shown to reduce significantly and dose-dependently the ATP-induced enhancement of citric acid-induced coughs in the guinea pig. These anti-tussive effects were obtained at a plasma concentration known to block P2X3 homotrimeric receptors, but at concentration 50-fold lower than that required to block P2X2/3 heterotrimeric receptors. These results indicate that the anti-tussive effect of BLU-5937 is primarily mediated through the inhibition of P2X3 homotrimeric receptors. In a rat behavioral taste model, BLU-5937 (10-20 mg/kg, IP) did not alter taste perception as compared to control animals. In the same experiment, N-00588 (10-20 mg/kg, IP), a weakly selective antagonist for P2X3 versus P2X2/3 receptors, had a significant inhibitory effect on taste perception. Pharmacokinetic analysis of drug plasma concentrations showed that BLU-5937 did not affect taste function at concentrations up to 30 times the IC50 for P2X3. These results suggest that N-00588 achieved systemic concentration that blocked P2X3 and P2X2/3 receptors expressed on gustatory nerve ending innervating taste buds. The lack of effect of BLU-5937, even at high doses, on taste perception may be attributed to its higher selectivity for the P2X3 versus P2X2/3 receptors on the taste buds. The safety, tolerability and pharmacokinetic profile of BLU-5937 was assessed in a battery of preclinical studies and have revealed that BLU-5937 exhibits excellent drug-like characteristics, including good oral bioavailability, low predicted clearance in human, no blood-brain barrier permeability and high safety margin versus human predicted efficacious exposure. BLU-5937 is currently in clinical phase I development stage. In conclusion, BLU-5937 was selected as a drug candidate for the treatment of chronic cough due to its high potency and selectivity for P2X3 homotrimeric receptors, strong anti-tussive effects, excellent tolerability and predicted pharmacokinetic properties in humans." @default.
• W2924783581 created "2019-04-01" @default.
• W2924783581 creator A5075874590 @default.
• W2924783581 creator A5090917504 @default.
• W2924783581 date "2019-06-01" @default.
• W2924783581 modified "2023-09-29" @default.
• W2924783581 title "BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration" @default.
• W2924783581 cites W11135432 @default.
• W2924783581 cites W1511198581 @default.
• W2924783581 cites W1544610129 @default.
• W2924783581 cites W1561513264 @default.
• W2924783581 cites W1577961500 @default.
• W2924783581 cites W1623121663 @default.
• W2924783581 cites W1977367528 @default.
• W2924783581 cites W1978099429 @default.
• W2924783581 cites W1986956014 @default.
• W2924783581 cites W1997082215 @default.
• W2924783581 cites W2001991082 @default.
• W2924783581 cites W2006815126 @default.
• W2924783581 cites W2019115048 @default.
• W2924783581 cites W2037429300 @default.
• W2924783581 cites W2063388276 @default.
• W2924783581 cites W2085463877 @default.
• W2924783581 cites W2088613999 @default.
• W2924783581 cites W2091992230 @default.
• W2924783581 cites W2098489429 @default.
• W2924783581 cites W2104726760 @default.
• W2924783581 cites W2107756388 @default.
• W2924783581 cites W2108134012 @default.
• W2924783581 cites W2110969445 @default.
• W2924783581 cites W2118446318 @default.
• W2924783581 cites W2124531992 @default.
• W2924783581 cites W2127376430 @default.
• W2924783581 cites W2127578476 @default.
• W2924783581 cites W2130770638 @default.
• W2924783581 cites W2142609868 @default.
• W2924783581 cites W2153822737 @default.
• W2924783581 cites W2155167132 @default.
• W2924783581 cites W2160749458 @default.
• W2924783581 cites W2418994609 @default.
• W2924783581 cites W2520531293 @default.
• W2924783581 cites W2613537908 @default.
• W2924783581 cites W89090350 @default.
• W2924783581 doi "https://doi.org/10.1016/j.pupt.2019.03.007" @default.
• W2924783581 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30902655" @default.
• W2924783581 hasPublicationYear "2019" @default.
• W2924783581 type Work @default.
• W2924783581 sameAs 2924783581 @default.
• W2924783581 citedByCount "64" @default.
• W2924783581 countsByYear W29247835812019 @default.
• W2924783581 countsByYear W29247835812020 @default.
• W2924783581 countsByYear W29247835812021 @default.
• W2924783581 countsByYear W29247835812022 @default.
• W2924783581 countsByYear W29247835812023 @default.
• W2924783581 crossrefType "journal-article" @default.
• W2924783581 hasAuthorship W2924783581A5075874590 @default.
• W2924783581 hasAuthorship W2924783581A5090917504 @default.
• W2924783581 hasConcept C15490471 @default.
• W2924783581 hasConcept C155164980 @default.
• W2924783581 hasConcept C160145004 @default.
• W2924783581 hasConcept C169760540 @default.
• W2924783581 hasConcept C170493617 @default.
• W2924783581 hasConcept C185592680 @default.
• W2924783581 hasConcept C2776217527 @default.
• W2924783581 hasConcept C2776885963 @default.
• W2924783581 hasConcept C2779245659 @default.
• W2924783581 hasConcept C2780071552 @default.
• W2924783581 hasConcept C55493867 @default.
• W2924783581 hasConcept C71924100 @default.
• W2924783581 hasConcept C86803240 @default.
• W2924783581 hasConcept C98274493 @default.
• W2924783581 hasConceptScore W2924783581C15490471 @default.
• W2924783581 hasConceptScore W2924783581C155164980 @default.
• W2924783581 hasConceptScore W2924783581C160145004 @default.
• W2924783581 hasConceptScore W2924783581C169760540 @default.
• W2924783581 hasConceptScore W2924783581C170493617 @default.
• W2924783581 hasConceptScore W2924783581C185592680 @default.
• W2924783581 hasConceptScore W2924783581C2776217527 @default.
• W2924783581 hasConceptScore W2924783581C2776885963 @default.
• W2924783581 hasConceptScore W2924783581C2779245659 @default.
• W2924783581 hasConceptScore W2924783581C2780071552 @default.
• W2924783581 hasConceptScore W2924783581C55493867 @default.
• W2924783581 hasConceptScore W2924783581C71924100 @default.
• W2924783581 hasConceptScore W2924783581C86803240 @default.
• W2924783581 hasConceptScore W2924783581C98274493 @default.
• W2924783581 hasLocation W29247835811 @default.
• W2924783581 hasLocation W29247835812 @default.
• W2924783581 hasOpenAccess W2924783581 @default.
• W2924783581 hasPrimaryLocation W29247835811 @default.
• W2924783581 hasRelatedWork W1999795314 @default.
• W2924783581 hasRelatedWork W2016593035 @default.
• W2924783581 hasRelatedWork W2018479387 @default.
• W2924783581 hasRelatedWork W2076997324 @default.
• W2924783581 hasRelatedWork W2087092938 @default.
• W2924783581 hasRelatedWork W2118626190 @default.
• W2924783581 hasRelatedWork W2137278164 @default.
• W2924783581 hasRelatedWork W231299636 @default.
• W2924783581 hasRelatedWork W2525708233 @default.

• next